How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

584 results for

Antithyroid Antibody

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

581. Antithyroid antibodies as an early marker for thyroid disease induced by amiodarone. (PubMed)

Antithyroid antibodies as an early marker for thyroid disease induced by amiodarone. Changes in thyroid function may occur during treatment with amiodarone. A double blind prospective trial of amiodarone and placebo was performed in 37 patients in the subacute phase of myocardial infarction. Though none of the patients assigned to receive placebo developed any antibody, six of 13 patients treated with amiodarone developed antithyroid microsomal antibodies. There was no difference (...) in triiodothyronine and thyroxine concentrations between the two groups, but a significant difference in concentrations of thyroid stimulating hormone was noted on day 30 (p less than 0.05). Six months after the withdrawal of amiodarone autoantibodies could not be detected and concentrations of thyroid stimulating hormone were normal. These antibodies have not previously been reported to develop during short term treatment with amiodarone. They could have an important role in the detection of early thyroid

Full Text available with Trip Pro

1986 British medical journal (Clinical research ed.) Controlled trial quality: uncertain

582. Evaluation of serum basal thyrotrophin levels and thyrotrophin receptor antibody activities as prognostic markers for discontinuation of antithyroid drug treatment in patients with Graves' disease. (PubMed)

Evaluation of serum basal thyrotrophin levels and thyrotrophin receptor antibody activities as prognostic markers for discontinuation of antithyroid drug treatment in patients with Graves' disease. We evaluated whether antithyroid drug treatment could be terminated more appropriately when both the serum basal thyrotrophin (TSH) level and TSH receptor antibody activity have become normal.This was a prospective randomized study of patients with Graves' disease followed for a mean of 28 months (...) after the withdrawal of antithyroid drug treatment.A total of 174 patients with hyperthyroid Graves' disease were entered consecutively into this study, 11 of whom were subsequently excluded. One hundred and sixty-three patients were divided randomly into two groups having different criteria for the discontinuation of the antithyroid drug. Group 1 consisted of 79 patients whose antithyroid drug treatment was discontinued if both their serum TSH level and thyrotrophin binding inhibitor immunoglobulin

1992 Clinical endocrinology Controlled trial quality: uncertain

583. The effects of prolonged lithium exposure on the immune system of normal control subjects: serial serum soluble interleukin-2 receptor and antithyroid antibody measurements. (PubMed)

The effects of prolonged lithium exposure on the immune system of normal control subjects: serial serum soluble interleukin-2 receptor and antithyroid antibody measurements. The purpose of this study was to begin evaluating the effects of lithium carbonate on in vivo immune function in normal controls. We postulated that lithium carbonate would stimulate lymphocytes but would not affect the production of antithyroid antibodies. Twenty-seven normal controls had blood samples drawn (...) with lithium treatment nor did lithium act as an adjuvant to increase the titers in subjects with preexisting antithyroid antibodies.

1994 Biological psychiatry Controlled trial quality: uncertain

584. Effects of l-thyroxine administration, TSH-receptor antibodies and smoking on the risk of recurrence in Graves' hyperthyroidism treated with antithyroid drugs: a double-blind prospective randomized study. (PubMed)

Effects of l-thyroxine administration, TSH-receptor antibodies and smoking on the risk of recurrence in Graves' hyperthyroidism treated with antithyroid drugs: a double-blind prospective randomized study. In Graves' hyperthyroidism treated with antithyroid drugs (ATD), the overall relapse rate reaches 30-50% following ATD discontinuation. Conflicting results have previously been reported with regard to the usefulness of combining ATD with thyroxine (l-T4), and thereafter maintaining l-T4 (...) the combined therapy. Following ATD discontinuation, the patients were randomly assigned (double-blind placebo-controlled trial) to taking 100 microg/day l-T4 (vs placebo) for an additional year.The following determinations were carried out at initial diagnosis: serum total T4 and tri-iodothyronine (T3), free T4 and T3, TSH, TSH-receptor antibodies (TSHR-Ab), thyroid scintigraphy and echography. During ATD treatment, serum free T4 and T3 and TSH concentrations were recorded after 1 (optional), 2, 4, 6, 9

2001 European journal of endocrinology / European Federation of Endocrine Societies Controlled trial quality: uncertain

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>